Chronic Kidney
Disease (CKD)
Management in
General Practice



Prevention • Support • Research



0800 KIDNEY (0800 543 639)

www.kidneys.co.nz

# Early detection of CKD using kidney health check

# Who is at higher risk of kidney disease?

- Age > 60 years if other risk factors present
- Diabetes
- High blood pressure
- Cardiovascular disease
- Smoking
- Obesity
- Family history of kidney disease
- Maori and Pacific people
- South Asians

# What should be done?

- Serum creatinine to determine eGFR
- Urine protein test

   ideally albumin/ creatinine ratio
   (UACR) on first
- void specimenBlood pressure

#### How often?

- If CKD not present At least every 1-2 years
- If Diabetes or CKD present
   At least every 12 months

Adapted from KHA-CARI Early CKD Guidelines 2013.

	Definitions of Albuminuria and Proteinuria			
Kidney damage stage	Urine albumin/creatinine ratio (mg/mmol)	24h urine albumin (mg/day)	Urine protein/creatinine ratio (mg/mmol)	24h urine protein (mg/day)
Normalbuminuria	Male <2.5 Female <3.5	<30	Male <4 Female <6	<50
Microalbuminuria	Male 2.5-25 Female 3.5-35	30-300	Male 4-40 Female 6-60	50-500
Macroalbuminuria	Male >25 Female >35	>300	Male >40 Female >60	>500

If first void specimen not possible use a "spot" (random) urine

IF UACR positive, repeat 1-2 times over 3 months for confirmation

If eGFR<60mL/min/1.73m<sup>2</sup>, repeat test within 14 days. Small fluctuations in GFR are common and are not necessarily indicative of progression

Clinically significant change in eGFR - drop of 20% or greater from baseline measure

### Clinical action plan

Based on a combination of kidney function (eGFR) and kidney damage (albuminuria/proteinuria)

eGFR (mL/min/1.73m <sup>2)</sup>	Description	Clinical Action Plan
90	Stage 1 CKD - kidney damage* with normal kidney function	Further investigation for CKD may be indicated in those at increased risk**:  • blood pressure
60-89	Stage 2 CKD - kidney damage* with mild kidney function	<ul> <li>assessment of proteinuria</li> <li>urinalysis</li> <li>Cardiovascular risk reduction:</li> <li>blood pressure</li> <li>lipids</li> <li>blood glucose</li> <li>lifestyle modification (smoking, weight, physical activity, nutrition, alcohol)</li> </ul>
45 - 59	Stage 3a CKD - mild-moderate √kidney function	As above, plus:  • monitor eGFR 3 monthly  • avoid nephrotoxic drugs  • prescribe antiproteinuric drugs (ACE inhibitors or ARBs) if appropriate  • address common complications  • ensure drug dosages appropriate for level of kidney function  • consider indications for referral to a nephrologist
30-44	Stage 3b CKD - moderate-severe ↓kidney function	As above plus: Refer patients wih diabetes to nephrology
15 - 29	Stage 4 CKD - severe	As above + referral to nephrologist is usually indicated for physical and psychosocial preparation for renal replacement therapy (dialysis, preemptive transplantation, transplantation) or conservative medical management
< 15	Stage 5 CKD - end-stage kidney disease	As above + referral to a nephrologist

<sup>\*</sup> imaging or biopsy abnormalities, or proteinuria/haematuria

Clinical tip

<sup>\*\*</sup> hypertension, diabetes, smoker, age > 60 yrs, obesity, family history of kidney disease, Maori and Pacific people, South Asians

## Referral to a nephrologist is not necessary if

- Stable eGFR ≥30 mL/min/1.73m²
- Urine ACR <30 m/mmol (with no haematuria)
- Controlled blood pressure

The decision to refer or not must always be individualised, and particularly in younger individuals the indications for referral may be less stringent.

#### Tips for referral:

- Familiarise yourself with your local nephrology unit's referral quidelines
- Don't refer to a nephrologist if targets of therapy are achieved.
- Pay attention to CVD risk reduction.
- Consider discussing management issues with a nephrologist in cases where uncertainty regarding referral exists.

#### Clinical tip

When referring to a nephrologist, ensure patient has had a recent kidney ultrasound, current blood chemistry, and quantification of proteinuria.



o8oo KIDNEY (o8oo 543 639)

www.kidneys.co.nz

# Indications for referral to a nephrologist

#### Appropriate referral is associated with

- reduced rates of progression to end stage kidney disease
- decreased need for and duration of hospitalisation
- increased likelihood of permanent dialysis access created prior to dialysis onset
- reduced initial costs of care following the commencement of dialysis
- increased likelihood of kidney transplantation
- decreased patient morbidity and mortality

# Who should usually be referred to a nephrologist?

#### Anyone with

- eGFR <30mL/min/1.73m<sup>2\*</sup>
- Persistent significant albuminuria (urine ACR >30mg/mmol)
- A consistent decline in eGFR from a baseline of <60mL/min/1.73m<sup>2</sup> (a decline >5mL/min/1.73m<sup>2</sup> over a six-month period which is confirmed on a least three separate readings)
- Glomerular haematuria with macroalbuminuria
- CKD and hypertension that is hard to get to target despite at least three anti-hypertensives
- Diabetes with eGFR <45mL/min/1.73m<sup>2\*\*</sup>
- Referral may not be appropriate if eGFR stable, proteinuria minor and cardiovascular risk reduction achieved
- \*\* New Zealand Primary Care Handbook 2012

www.health.govt.nz/publication/new-zealand-primary-care-handbook-2012

#### Clinical tip

Urine protein:creatinine ratio of 100 mg/mmol ≅ daily protein excretion of 1g/24hrs

### Treatment targets for people with CKD

Parameter	Target	Treatment and effects on systolic BP	
Lifestyle Factors			
Smoking	Cease smoking	Lifestyle modification - refer to New Zealand Primary Care Handbook 2012*	
Weight	BMI at least $\leq$ 30 and ideally $\leq$ 25 kg/m <sup>2</sup> Waist circ males $<$ 102 cm Waist circ females $<$ 88cm	Lifestyle modification -  refer to Handbook  SBP reduction 5-20 mmHg ≃ 10 kg loss	
Physical activity	≥30 mins moderately intensive physical activity/day (3-6 METs)	Lifestyle modification - refer to Handbook and "Green Prescriptions" **	
		SBP reduction = 4-9 mmHg	
Nutrition	Dietary salt intake ≤ 100 mmol/day (6g salt/day)  Dietary protein intake - normal protein diet (0.75 - 1.0 g/kg/day, with adequate energy). Low protein diet not recommended	Lifestyle modification - refer to Handbook SBP reduction = 2-8 mmHg	
Alcohol	Reduce long-term health risks by drinking no more than:  • 2 standard drinks a day for women and no more than 10 standard drinks a week  • 3 standard drinks a day for men and no more than 15 standard drinks a week  AND at least two alcohol-free days every week	Lifestyle modification - refer to Health Promotion Agency*** Recommended upper limts for safer drinking SBP reduction = 2-4 mmHg	
Clinical Factors			
Blood pressure	≤140/90 mmHg ≤130/80 mmHg if albuminuria or diabetes	Lifestyle modification ACE inhibitor or ARB first line therapy Combination therapy with both ACEs and ARBs should be avoided	
Proteinuria	>50% reduction of baseline value	ACE inhibitor or ARB first line therapy	
Lipids	Total cholesterol <4.0 mmol/L LDL cholesterol <2.0 mmol/L HDL cholesterol ≥1.0 mmol/L Triglycerides <1.7 mmol/L	Drug treatment and specific lifestyle advice Treatment based on individual cardiac risk Statins less effective wih advanced CKD	
Blood glucose (for people with diabetes)	Pre-prandial BSL 4.0 - 6.0 mmol/L HbA1c <53 mmol/mol	Lifestyle modification* Oral short-acting hypoglycaemics Insulin Use metformin with caution if GFR 30-60 mL/min/1.73m <sup>2</sup> Avoid if GFR <30 mL/min/17.3m <sup>2</sup>	

Consider immunisation against influenza and invasive pneumococcal disease for people with diabetes or CKD.

#### **Golden Rules!**

People with moderate or severe CKD are at very high risk of a CVD event

Achieving adequate BP targets will often require the use of more than one agent

As eGFR declines more drugs will typically be required to achieve target blood pressure

<sup>\*</sup>www.health.govt.nz/publication/new-zealand-primary-care-handbook-2012

<sup>\*\*</sup>www.health.govt.nz/our-work/preventative-health-wellness/physical-activity/green-prescriptions

<sup>\*\*\*</sup>www.alcohol.org.nz

Prognosis of CKD by GFR and albuminuria category*					
		Albuminuria stage			
Kidney function stage	GFR (mL/min/1.73m <sup>2</sup> )	Normal (urine ACR mg/mmol) Male: < 2.5 Female: < 3.5	Microalbuminuria (urine ACR mg/mmol) Male: 2.5-25 Female: 3.5-35	Macroalbuminuria (urine ACR mg/mmol) Male: > 25 Female: > 35	
1	≥90	Not CKD unless haematuria, structural or			
2	60-89	pathological abnormalities present			
3a	45-59				
3b	30-44				
4	15-29				
5	<15 or on dialysis				

Risks of progressve CKD denoted as low , moderate , high , and very high

# Interpreting tests of GFR and albuminuria

- For patients with CKD, the combination of a low GFR <u>and</u> albuminuria or proteinuria places them at a greater risk of CKD progression at all ages, than those with just low GFR or albuminuria/proteinuria
- Repeated testing is needed to pick up the patient with rapidly deteriorating kidney function (a sustained decline in eGFR of more than 5ml/min/1.73m<sup>2</sup>/yr)
- A measured or estimated GFR <45mL/min/1.73m<sup>2</sup> is associated with increased risks of adverse renal, cardiovascular and other clinical outcomes, irrespective of age

<sup>\*</sup> Johnson DW, Atai E, Chan M, Phoon KS, Scott C, Toussaint ND, et al. KHA-CARI Guideline: Early chronic kidney disease: detection, prevention and management. Nephrology 2013; 18: 340-350.

## CKD management according to stage

CKD Stage	1	2	3	4	5
Description	Kidney damage + normal or 1eGFR	Kidney damage + mild √eGFR	Moderate √eGFR	Severe ↓eGFR	End-stage kidney disease
eGFR(ml/min/ 1.73m²)	≥ 90	60 - 89	30 - 59	15 - 29	< 15 or on dialysis
Common Signs and Symptoms	Nil		Nil or nocturia, mild malaise, anorexia	As for stage 3 + nausea, pruritis, restless legs, dyspnoea	As for stage 4
Common Complications	Hypertension		As for stage 1-2 + Anaemia Sleep Apnoea CVD Malnutrition	As for stage 3 + Hyperphosphata emia Acidosis Hyperkalaemia Restless legs	As for stage 4 + Pericarditis Encephalopathy Neuropathy
Clinic Assessment	BP Weight Urinalysis		As for stage 1-2	As for stage 1-2 + Fluid overload	As for stage 4
Lab Assessment	General chemistry, eGFR Glucose Lipids Albuminuria or proteinuria		As for stage 1-2 + FBC Iron stores Ca/P04 PTH (repeat test on nephrologist advice)	As for stage 3 + plasma bicarbonate	As per monthly blood schedule specified by Renal Unit
Management	≤ 140/90 or ≤ 130/80 if albuminuria		As for stage 1-2 + Treat complications Medication review	As for stage 3 + Education regarding treatment options including pre- emptive transplantation Dialysis access surgery	As for stage 4 + Dialysis or transplantation (or conservative medical management)
Frequency of clinical review	6 - 12 months Less frequently if eGFR stable and treatment targets met		3 - 6 monthly	3 monthly	Monthly (shared with renal unit)
Nephrologist Referral	Consider referral if indication is present		Consider referral if indication is present	All patients should be referred to a nephrologist	All patients should be referred to a nephrologist